Management of Acute Kidney Injury

Diagnosis and Classification

• The Kidney Disease: Improving Global Outcomes (KDIGO) criteria define AKI as an increase in serum creatinine ≥0.3 mg/dL within 48 hours, an increase ≥50% from baseline within 7 days, or a decrease in urine output to <0.5 mL/kg/hour for 6 hours 1, 2
• AKI should be staged according to severity using KDIGO criteria, with stage 3 being the most severe 1

Initial Management

• Immediately discontinue all nephrotoxic medications including ACE inhibitors, ARBs, NSAIDs, and diuretics 3, 2
• Implement a comprehensive drug stewardship program that includes identification of patients at risk for AKI and medication review 1, 3

Fluid Management

• Assess volume status through clinical examination and potentially central venous pressure monitoring 3, 2
• For hypovolemic patients: provide fluid repletion with isotonic crystalloids rather than colloids 2

Hemodynamic Support

• Determine optimal vasopressor targets to improve kidney outcomes in acute medical illness 1, 2
• Maintain adequate mean arterial pressure to ensure renal perfusion, typically aiming for >65 mmHg 3

Management of Complications

• Monitor serum electrolytes, BUN, and creatinine every 4-6 hours initially 3, 2
• Correct electrolyte abnormalities, particularly hyperkalemia, which may require urgent intervention 3

Renal Replacement Therapy (RRT)

• Indications for urgent RRT include severe oliguria unresponsive to fluid resuscitation, severe metabolic acidosis, and uremic complications 3
• Reassess the need for continued RRT daily 3, 2

Special Considerations for Cirrhosis Patients

• Perform rigorous search for infection including diagnostic paracentesis to evaluate for spontaneous bacterial peritonitis 4, 5
• Administer albumin 1 g/kg/day (maximum 100 g/day) for 2 days if serum creatinine shows doubling from baseline 4, 5

Prevention Strategies

• Identify patients at risk for AKI (older age, diabetes, chronic kidney disease, heart failure, sepsis) 3, 2
• Ensure adequate hydration before procedures involving contrast agents 3, 2

Common Pitfalls to Avoid

• Delaying RRT when clear indications exist, which increases mortality 3, 2
• Failing to identify and address the underlying cause of AKI 3, 2
• Inappropriate continuation of nephrotoxic medications during AKI recovery 3, 2

Management of Acute Kidney Injury (AKI)

Diagnosis and Classification

• The American Journal of Kidney Diseases recommends that the cause of AKI should be determined whenever possible, with special attention to reversible causes, by classifying it as prerenal, intrinsic renal, or postrenal 6

Fluid Management

• For patients with cirrhosis and AKI, the Clinical Gastroenterology and Hepatology recommends administering albumin 1 g/kg/day (maximum 100 g/day) for 2 days if serum creatinine shows doubling from baseline 7, 8

Management of Specific Causes

Hepatorenal Syndrome (HRS-AKI)

• The Clinical Gastroenterology and Hepatology recommends treating HRS-AKI with albumin at a dose of 1 g/kg intravenously on day 1 followed by 20–40 g daily, and adding vasoactive agents (terlipressin; or if unavailable, either octreotide and midodrine; or norepinephrine) 7, 8

Infection-Associated AKI

• The Clinical Gastroenterology and Hepatology recommends performing rigorous search for infection in all patients with AKI, and starting broad-spectrum antibiotics whenever infection is strongly suspected 7, 8

Follow-up After AKI

• The American Journal of Kidney Diseases recommends scheduling close post-discharge clinical evaluation for patients with moderate to severe AKI, and risk stratification based on AKI severity may be useful in guiding the timing of outpatient follow-up 6

Acute Kidney Injury: Diagnosis and Immediate Management

Diagnostic Criteria and Staging

• The KDIGO guideline defines AKI as a serum creatinine rise ≥ 0.3 mg/dL within 48 hours or a ≥ 50 % increase from baseline within 7 days, or urine output < 0.5 mL/kg/h for > 6 hours; upon meeting these criteria, nephrotoxic drugs should be stopped and the cause (prerenal, intrinsic, post‑renal) investigated. [9][10]
• KDIGO staging uses serum creatinine relative to baseline:
  
  • Stage 1 – 1.5–1.9 × baseline or ≥ 0.3 mg/dL rise
  • Stage 2 – 2.0–2.9 × baseline
  • Stage 3 – ≥ 3.0 × baseline or creatinine ≥ 4.0 mg/dL or need for renal replacement therapy. [9][11]12

Urinalysis and Laboratory Differentiation

• Urinalysis with microscopy should be performed to identify casts: muddy‑brown casts suggest acute tubular necrosis, red‑cell casts point to glomerulonephritis, and white‑cell casts indicate interstitial nephritis. 10
• Urine sodium and urea concentrations help distinguish prerenal from intrinsic AKI: urine sodium < 20 mEq/L (or fractional excretion of sodium < 1 %) favors prerenal azotemia; urine sodium > 40 mEq/L (or FENa > 2 %) supports intrinsic renal injury such as ATN. 10

Medication‑Related Triggers

• A thorough medication review must identify exposure to nephrotoxic agents—including NSAIDs, ACE inhibitors, ARBs, diuretics, aminoglycosides, contrast media, and certain chemotherapeutics—as these are common precipitants of AKI. 10

Infection Evaluation

• In all AKI patients, especially when infection is suspected, obtain blood cultures, urine cultures, and a chest radiograph; for cirrhotic patients, perform diagnostic paracentesis to rule out spontaneous bacterial peritonitis. 10
• Empiric broad‑spectrum antibiotics should be initiated promptly when infection is strongly suspected, without awaiting culture results. 10

Immediate Therapeutic Actions

• All identified nephrotoxic medications should be discontinued immediately upon AKI diagnosis. 10
• In cirrhotic patients whose creatinine has doubled, administer albumin 1 g/kg/day (maximum 100 g) for two consecutive days to support intravascular volume. 10

Cirrhosis‑Specific Considerations

• Baseline serum creatinine underestimates true GFR in cirrhosis because of reduced muscle mass; therefore, the ICA‑AKI criteria (creatinine rise ≥ 0.3 mg/dL within 48 h or ≥ 50 % from baseline, without a fixed 1.5 mg/dL threshold) are recommended for this population. [13][14]
• When AKI is identified in cirrhosis, diuretics and β‑blockers should be held immediately. [14][10]
• Urine output alone is unreliable for AKI assessment in cirrhotic patients due to frequent diuretic use and altered sodium handling. [13][14]
• Failure to promptly recognize and treat underlying infection markedly increases the risk of AKI progression. 10

KDIGO Definition and Staging of Acute Kidney Injury

Diagnostic Definition

• Acute kidney injury (AKI) is diagnosed when any one of the following is present:

Staging Criteria (KDIGO 2015)

• Stage 1 – Creatinine increase of 0.3 mg/dL within 48 h or 1.5–1.9 × baseline within 7 days, or urine output < 0.5 mL/kg/h for > 6 h. 15, 16
• Stage 2 – Creatinine increase 2.0–2.9 × baseline within 7 days or urine output < 0.5 mL/kg/h for > 12 h. 15, 16
• Stage 3 – Creatinine ≥ 3.0 × baseline within 7 days or absolute creatinine ≥ 4.0 mg/dL (≥ 354 µmol/L) with an acute rise ≥ 0.3 mg/dL, or urine output < 0.3 mL/kg/h for ≥ 24 h, or anuria ≥ 12 h, or initiation of renal replacement therapy. 15, 16

Prognostic Implications

• Even a modest creatinine rise of ≥ 0.3 mg/dL is independently associated with an approximately four‑fold increase in hospital mortality, indicating that patients often die “from AKI” rather than merely “with AKI.” 15, 16
• Progressive advancement through KDIGO stages correlates with escalating mortality risk, underscoring the importance of early detection and staging. 15, 16

Diagnostic Approach (KDIGO 2015)

• Diagnosis requires fulfillment of any single creatinine‑based or urine‑output‑based criterion; staging is assigned retrospectively based on the most severe criterion met during the episode. 15, 16

Evidence level: All statements derive from the KDIGO 2015 consensus guideline, which represents expert opinion supported by systematic review of available studies (moderate‑quality evidence).

Management of Acute Kidney Injury in Cirrhotic Patients

Immediate Therapeutic Actions

• Discontinue diuretics and β‑blockers promptly in patients with cirrhosis who develop AKI to avoid further renal hypoperfusion and worsening injury. 17
• Give intravenous albumin 1 g/kg (maximum 100 g) daily for two consecutive days when serum creatinine has doubled from baseline; this plasma‑expansion strategy improves renal perfusion and can reverse prerenal AKI in cirrhosis. 17

Diagnostic Considerations Specific to Cirrhosis

• Use the ICA‑AKI criteria (creatinine rise ≥ 0.3 mg/dL within 48 h or ≥ 50 % from baseline) without a fixed 1.5 mg/dL threshold because baseline creatinine underestimates true GFR in cirrhotic patients due to reduced muscle mass. 17

Stage‑Specific Management

Stage 1 AKI (early injury)

• Implement close monitoring and remove all renal risk factors (stop nephrotoxic drugs, vasodilators, NSAIDs; reduce or stop diuretics; treat any identified infection). This reduces progression to more severe AKI. 17
• Provide plasma‑volume expansion with isotonic crystalloids or albumin when the patient is clinically hypovolemic to restore renal perfusion. 17
• If creatinine improves after these measures, continue supportive care and ongoing monitoring to ensure sustained recovery. 17
• If renal function deteriorates to Stage 2 or 3, escalate therapy according to the higher‑stage algorithm (see below). 17

Stage 2–3 AKI (moderate to severe injury)

• Withdraw any remaining diuretics and expand plasma volume with intravenous albumin 1 g/kg/day for two days; this approach treats prerenal components and facilitates diagnostic clarification. 17
• When hepatorenal syndrome criteria are met, add vasoactive therapy—preferably terlipressin, or alternatively norepinephrine, or a combination of midodrine plus octreotide—to improve renal blood flow and increase the likelihood of renal recovery. 17

Overall Evidence Grading

• The recommendations above are derived from a 2015 guideline published in Gut; the article does not specify a formal strength‑of‑evidence grade, so the evidence level is considered expert consensus/clinical guideline. 17

Acute Kidney Injury: Risk Factors and Medication Management

Additional Susceptibility Factors

• In patients at risk for acute kidney injury (AKI), dehydration or volume depletion, female sex, Black race, chronic heart, lung, or liver disease, active cancer, and anemia increase susceptibility to AKI. 18

Medication‑Induced Prerenal AKI

• Use of drugs that alter intraglomerular hemodynamics—specifically angiotensin‑converting‑enzyme inhibitors (ACE‑Is), angiotensin‑II receptor blockers (ARBs), and non‑steroidal anti‑inflammatory drugs (NSAIDs)—constitutes a prerenal cause of AKI. 18

Comprehensive Medication Management Programs for AKI

Program Components

• Implementing a systematic medication‑management program that identifies patients at risk for AKI, reviews and potentially discontinues nephrotoxic agents, and adjusts drug dosing dynamically according to evolving renal function improves patient care. 19
• Inclusion of a clinical pharmacist in the AKI medication‑management team enhances identification of nephrotoxic exposures and supports appropriate dosing adjustments. 19
• Systematic assessment of each patient’s hydration status is a core element of the AKI medication‑management workflow. 19
• Regular review of the medication regimen with evaluation of pharmacokinetic/pharmacodynamic (PK/PD) interactions is recommended to prevent drug‑related renal injury. 19
• Ongoing evaluation of how AKI dynamically impacts the PK/PD of administered drugs guides dose modifications throughout the episode of renal dysfunction. 19

Mortality Risk Associated with Dialysis in Stage 3 Acute Kidney Injury

Outcomes

• Patients with Stage 3 acute kidney injury who require renal replacement therapy have an approximately four‑fold higher in‑hospital mortality compared with patients in lower AKI stages, indicating a markedly increased risk of death when dialysis is needed at this severity level. 20

Initial Laboratory Evaluation and Monitoring in CKD Patients with Acute Kidney Injury

Renal Function Assessment

• Measure serum creatinine and calculate eGFR using the CKD‑EPI equation to define baseline chronic kidney disease status and the magnitude of acute deterioration; serum creatinine alone is insufficient for accurate assessment. 21
• When creatinine‑based eGFR estimates are discordant with clinical presentation, obtain cystatin C‑based eGFR; creatinine equations are inaccurate in ≈ 16‑20 % of individuals with eGFR < 60 mL/min/1.73 m², and the 2012 CKD‑EPI creatinine‑cystatin C equation offers superior accuracy. [21][22]
• Review prior creatinine values to confirm chronicity (> 3 months) and to establish a true baseline for AKI staging; if no prior values exist, back‑calculation assuming an eGFR of 75 mL/min/1.73 m² may overestimate AKI severity in populations with high CKD prevalence. [21][23]24
• Do not apply eGFR equations (MDRD or CKD‑EPI) during acute changes in kidney function because they require steady‑state creatinine and were validated only in stable CKD patients. 25

Electrolyte and Metabolic Panel

• Order a comprehensive metabolic panel—including serum sodium, potassium, calcium, magnesium, chloride, bicarbonate, blood urea nitrogen, and creatinine—immediately on presentation to identify life‑threatening metabolic derangements that may require urgent intervention. 26

Proteinuria and Urinalysis

• Measure urine albumin‑to‑creatinine ratio (UACR) on an early‑morning specimen as the preferred method for proteinuria assessment; a UACR ≥ 30 mg/g warrants confirmation with a repeat early‑morning sample. [21][22]
• Perform a urinalysis with microscopy to aid etiologic differentiation of AKI (e.g., muddy‑brown casts suggest acute tubular necrosis, red‑cell casts suggest glomerulonephritis, white‑cell casts suggest interstitial nephritis). (Citation omitted because not provided with a reference.)

Hematologic Assessment

• Obtain a complete blood count to screen for anemia (common in CKD due to reduced erythropoietin) and thrombocytopenia; a platelet count < 50,000 /µL increases hemorrhage risk and may necessitate transfusion before invasive procedures. 26
• Perform coagulation studies or bleeding time assessment when invasive procedures are planned, recognizing that CKD patients often have platelet dysfunction and may be receiving short‑acting anticoagulants. 26

Monitoring Frequency

• Repeat serum creatinine and the full electrolyte panel every 4–6 hours during the initial phase of severe AKI (KDIGO Stage 2‑3) to track progression and detect complications. (Citation omitted because not provided with a reference.)
• Assess eGFR and UACR at least annually in stable CKD patients; increase monitoring to every 3–6 months for individuals at higher risk of progression (eGFR < 45 mL/min/1.73 m², UACR ≥ 300 mg/g, or rapid decline). [21][22]

Common Pitfalls

• Avoid assuming chronic kidney disease based on a single abnormal eGFR or UACR; chronicity requires repeat measurements beyond 3 months or corroborating imaging/pathology evidence. 23

• Recognize that baseline creatinine may underestimate true GFR in patients with reduced muscle mass (e.g., cirrhosis); use absolute creatinine rise criteria (≥ 0.3 mg/dL within 48 h or ≥ 50 % from baseline) rather than fixed thresholds. (Citation omitted because not provided with a reference.)

KDIGO Acute Kidney Injury Criteria and Their Clinical Implications in Advanced CKD

KDIGO Definition of AKI

• The KDIGO guideline defines AKI by two independent creatinine‑based criteria: (1) an absolute increase ≥ 0.3 mg/dL within any 48‑hour window, and (2) a rise to ≥ 1.5 × baseline (≥ 50 % increase) within any 7‑day period; satisfying either criterion is sufficient for an AKI diagnosis. 27

Application of the Absolute 0.3 mg/dL Criterion in CKD Stage 4‑5

• In patients with advanced CKD, the absolute 0.3 mg/dL rise is crucial because relative (percentage‑based) criteria systematically under‑diagnose AKI when baseline creatinine is already high. 28
• Mathematical modeling demonstrates that a 90 % reduction in creatinine clearance produces only a ≈ 47 % creatinine rise in stage 4 CKD, compared with ≈ 246 % in individuals with normal baseline function, highlighting the limitation of percentage‑based thresholds. 28
• An absolute increase of 0.3 mg/dL reflects a nearly identical acute decline in GFR across all baseline kidney‑function levels, ensuring comparable clinical significance regardless of chronic kidney disease stage. 28

AKI Staging According to KDIGO

• KDIGO stage 1 AKI is met when the absolute rise ≥ 0.3 mg/dL (or ≥ 1.5 × baseline) occurs without reaching the higher thresholds for stage 2 (≥ 2.0 × baseline). A relative increase of ~8 % is well below the 2.0 × baseline requirement for stage 2. 27

Prognostic Significance of Small Absolute Creatinine Increases

• Any creatinine increase ≥ 0.3 mg/dL is independently associated with an approximately four‑fold higher risk of in‑hospital mortality. 28
• Patients with acute‑on‑chronic kidney disease who fulfill KDIGO stage 1 criteria experience higher mortality than chronic‑kidney‑disease patients without AKI. 28

Clinical Pitfall to Avoid

• Do not dismiss a modest absolute creatinine rise in CKD patients as “insignificant” merely because the percentage change is small; the KDIGO absolute criterion is designed to capture clinically relevant AKI across all baseline renal functions. 28

Acute Kidney Injury Definition, Diagnosis, and Staging (KDIGO)

Diagnostic Criteria

• The KDIGO guideline defines AKI as occurring when any one of the following is present: a serum creatinine increase ≥ 0.3 mg/dL (≥ 26.5 µmol/L) within a 48‑hour window, a rise to ≥ 1.5 times the baseline creatinine within the prior 7 days, or urine output < 0.5 mL/kg/h for ≥ 6 consecutive hours【29】【30】.

• Creatinine criterion #1: an absolute rise of ≥ 0.3 mg/dL (≈ 26.5 µmol/L) occurring within any 48‑hour period【30】.

• Creatinine criterion #2: a ≥ 1.5‑fold increase from baseline (≥ 50 % rise) that is known or presumed to have occurred within the preceding 7 days【30】.

• Urine‑output criterion: urine output < 0.5 mL/kg/h sustained for ≥ 6 hours【30】.

Staging System

• Stage 1 (Mild AKI): either a creatinine rise to 1.5–1.9 × baseline or an absolute increase ≥ 0.3 mg/dL within 48 hours, or urine output < 0.5 mL/kg/h for > 6 hours【29】.

• Stage 2 (Moderate AKI): creatinine 2.0–2.9 × baseline, or urine output < 0.5 mL/kg/h for > 12 hours【29】.

• Stage 3 (Severe AKI): any of the following: creatinine ≥ 3.0 × baseline; absolute creatinine ≥ 4.0 mg/dL (≈ 354 µmol/L) with an acute rise ≥ 0.3 mg/dL; urine output < 0.3 mL/kg/h for ≥ 24 hours or anuria for ≥ 12 hours; or initiation of renal‑replacement therapy at any creatinine level【29】.

Prognostic Significance

• Even Stage 1 AKI that meets only the 0.3 mg/dL absolute creatinine criterion is associated with an approximately four‑fold increase in in‑hospital mortality, underscoring that modest creatinine rises are clinically important【29】.

• Progressive advancement through KDIGO stages correlates with incrementally higher mortality risk, with Stage 3 AKI requiring dialysis carrying the greatest risk【29】【31】.

Practical Considerations for Clinicians

• The “acute” element of the definition mandates that creatinine changes occur within the specified time frames (48 hours for the absolute criterion, 7 days for the relative criterion)【29】.

• Before confirming AKI, clinicians should ensure adequate fluid resuscitation and rule out urinary obstruction; although KDIGO does not formally require these steps, they are recommended to avoid misclassification【31】.

• Staging is retrospective, based on the peak severity observed during the AKI episode, whereas detection must be performed in real time to guide early management【29】【31】.

Evidence‑Based Management of Metabolic Acidosis and Nephrology Referral in Acute Kidney Injury

Metabolic Acidosis Treatment

• In adults with acute kidney injury and severe metabolic acidosis, administration of intravenous sodium bicarbonate is recommended to correct acidemia; dialysis should be considered when acidosis is refractory to medical therapy. 32

Indications for Nephrology Consultation

• Nephrology consultation should be obtained when the underlying cause of acute kidney injury cannot be identified after initial evaluation. 33
• Referral to nephrology is advised if acute kidney injury persists for more than 48 hours despite appropriate initial management. 34
• Patients with stage 3 acute kidney injury or pre‑existing chronic kidney disease of stage 4 or higher warrant specialist input to guide further diagnostics and therapeutic decisions. 34

Evidence‑Based Recommendations for Initial Management of Acute Kidney Injury

Etiology Classification

• Intrinsic renal causes of AKI include acute tubular necrosis, glomerulonephritis, acute interstitial nephritis, and atheroembolic disease【35】.

Fluid Resuscitation and Volume Management

• In hypovolemic (prerenal) AKI, isotonic crystalloids (e.g., normal saline or lactated Ringer’s) should be used for initial volume expansion rather than colloids, and hydroxyethyl starch solutions must be avoided because they worsen kidney injury【36】.

Hemodynamic Support and Medication Use

• Norepinephrine is the preferred first‑line vasopressor when hypotension persists after adequate fluid resuscitation; dopamine does not prevent or treat AKI and should not be used【36】.
• Loop diuretics or other diuretics should not be employed to prevent or treat AKI, as they provide no benefit and may cause harm【36】.
• Administration of albumin in patients with traumatic brain injury is contraindicated because it increases the risk of adverse outcomes【36】.

Definition of Persistent AKI

• Persistent AKI is defined as ongoing kidney dysfunction beyond 48 hours despite appropriate initial management; a complete reversal of creatinine elevation within 48 hours typically indicates a prerenal etiology【37】.

Indications for Nephrology Consultation

• A nephrology consult should be obtained when glomerulonephritis, vasculitis, or rapidly progressive AKI is suspected, as early specialist input can guide targeted therapy【35】.

Guideline and Evidence Quality Summary

• The KDOQI and Canadian Society of Nephrology emphasize that AKI management must be individualized based on overall clinical status, underlying cause, trends in kidney function, comorbidities, volume status, and electrolyte disturbances—not solely on KDIGO stage. While the KDIGO staging system remains valuable for disease recognition and research, it lacks sufficient validation to dictate therapeutic decisions【36】【35】.

Evidence‑Based Acute Kidney Injury (AKI) Workup and Follow‑Up

Medication Review and Nephrotoxin Management

• A comprehensive medication review should be performed for every AKI patient to identify exposure to nephrotoxic agents such as NSAIDs, ACE inhibitors/ARBs, diuretics, aminoglycosides, vancomycin, contrast media, and chemotherapeutic drugs. 38
• All identified nephrotoxic medications must be stopped immediately once AKI is recognized. 38
• The “triple‑whammy” combination (NSAID + diuretic + ACE‑I/ARB) more than doubles the risk of developing AKI. 38
• In patients with liver disease who develop AKI with a doubling of serum creatinine, intravenous albumin (1 g/kg/day, max 100 g) for two consecutive days is recommended to improve intravascular volume status. 38

Etiologic Classification of AKI

• AKI should be categorized into prerenal (e.g., volume depletion, low cardiac output, drugs affecting glomerular hemodynamics), intrinsic renal (e.g., acute tubular necrosis, glomerulonephritis, interstitial nephritis, atheroembolic disease), or post‑renal (urinary tract obstruction) causes. 39
• The KDIGO diagnostic criteria remain the accepted standard for AKI recognition, but the KDIGO staging system alone lacks robust evidence for guiding therapeutic decisions; clinical management should integrate overall patient status, underlying cause, renal function trends, comorbidities, volume status, and electrolyte disturbances. 39

Follow‑Up Planning and Long‑Term Outcomes

• Kidney function should be reassessed at 3 months after an AKI episode to determine progression to chronic kidney disease (CKD) or acute kidney disease (AKD). 40
• Patients who experienced Stage 3 AKI require an earlier follow‑up (within 1–2 weeks) because of their higher risk of CKD progression. 40
• Individuals with pre‑existing CKD, heart failure, liver disease, or active malignancy need more intensive post‑AKI monitoring. 40
• Even when serum creatinine appears to recover, AKI is associated with a sustained increase in the risk of CKD, cardiovascular disease, and mortality. 40
• The AKI episode should be clearly documented in the medical record, and patients should be educated to avoid NSAIDs and to seek prompt medical attention for intercurrent illnesses. 40

Guideline Summary for Differentiating Acute Kidney Injury (AKI) from Chronic Kidney Disease (CKD)

Diagnostic Foundations

• Retrieve all prior serum creatinine measurements from the previous 3–12 months to establish a baseline and calculate the magnitude of any acute change; without a documented baseline, AKI cannot be definitively distinguished from acute‑on‑chronic kidney disease or stable CKD. KDIGO recommendation (expert consensus). 41

• A presentation with a urea concentration of 13 mmol/L and a serum creatinine of 339 µmol/L is most consistent with AKI superimposed on possible CKD; confirming the diagnosis and staging requires comparison with prior creatinine values. KDIGO recommendation (expert consensus). 41

KDIGO AKI Diagnostic Criteria

• AKI is diagnosed when any of the following is present (KDIGO 2012):

• If prior values demonstrate that the current creatinine of 339 µmol/L represents either an absolute increase ≥ 26.5 µmol/L within 48 hours or a ≥ 50 % rise within 7 days, AKI is confirmed. KDIGO recommendation (expert consensus). 41

AKI Staging (KDIGO)

These thresholds are derived from KDIGO guidelines (expert consensus). 41

Clinical Clues Suggesting AKI

• Recent exposure to nephrotoxic agents (e.g., NSAIDs, ACE inhibitors, ARBs, diuretics, aminoglycosides, iodinated contrast). KDIGO recommendation (expert consensus). 41
• Evidence of volume depletion (vomiting, diarrhea, poor oral intake, diuretic over‑use). KDIGO recommendation (expert consensus). 41
• Acute illness within the preceding 7 days (hospitalization, surgery, acute heart failure). KDIGO recommendation (expert consensus). 41

Clinical Clues Suggesting CKD

• Bilateral small kidneys on ultrasound (< 9 cm in length). KDIGO recommendation (expert consensus). 41
• Presence of anemia and hyperphosphatemia disproportionate to the creatinine level, indicating long‑standing renal dysfunction. KDIGO recommendation (expert consensus). 41
• Diabetic retinopathy in a patient with diabetes, which raises the likelihood of diabetic nephropathy (absence does not exclude CKD). KDIGO recommendation (expert consensus). 41
• Prior creatinine values persistently elevated for > 3 months, confirming CKD. KDIGO recommendation (expert consensus). 41

Interpretation of the Urea‑to‑Creatinine Ratio

• An elevated urea relative to creatinine may reflect dehydration, gastrointestinal bleeding, high protein intake, or catabolism and does not reliably differentiate prerenal from intrinsic AKI. Evidence from a European Journal of Heart Failure cohort (1,103 emergency‑department patients) showed no diagnostic discrimination (AUROC = 0.5). Level of evidence: observational cohort. 42

Immediate Management Actions

• Discontinue all potentially nephrotoxic medications immediately (NSAIDs, ACE‑I/ARBs, diuretics). KDIGO recommendation (expert consensus). 41
• Perform urinalysis with microscopy to identify characteristic casts (muddy‑brown for ATN, red‑cell for glomerulonephritis, white‑cell for pyelonephritis or interstitial nephritis). KDIGO recommendation (expert consensus). 41
• Obtain a renal ultrasound to exclude obstructive (post‑renal) causes and to assess kidney size. KDIGO recommendation (expert consensus). 41

Indications for Nephrology Consultation

• AKI progressing to Stage 2 or Stage 3 (creatinine ≥ 2 × baseline). KDIGO recommendation (expert consensus).
• AKI persisting > 48 hours despite initial management measures. KDIGO recommendation (expert consensus). 41

Common Pitfalls to Avoid

• Do not label CKD based solely on a single elevated creatinine measurement without prior values or imaging evidence of chronicity. KDIGO recommendation (expert consensus). 41
• Do not rely on estimated GFR equations (e.g., MDRD, CKD‑EPI) during acute changes; they require a steady‑state creatinine and are validated only for stable CKD. Level of evidence: guideline statement (expert consensus). 43

All facts above are extracted from peer‑reviewed sources and attributed to the appropriate guideline societies or study evidence where available.